PTC Inc. operates as software company in the Americas, Europe, and the Asia Pacific. The company provides Windchill, a suite that manages all aspects of the product development lifecycle(PLM) that provides real-time information sharing, dynamic data visualization, collaborate across geographically distributed teams, and enabling manufacturers to elevate product development, manufacturing, field service, and end-of-life processes; ThingWorx, an Industrial Internet of Things software; ServiceMax, a service lifecycle management solutions enable companies to asset uptime with optimized in-person and remote service and technician productivity with mobile tools, and deliver metrics; and Arena, a SaaS PLM solution enables product teams to collaborate virtually to share product and quality information with internal teams and supply chain partners and deliver products to customers. It offers Codebeamer, an application lifecycle management for products and software development; Servigistics, a service parts management solution; and FlexPLM, a platform for merchandising and line planning, materials management, sampling, and others. In addition, it offers Kepware, an enterprise industrial connectivity solution; Creo, a 3D CAD technology enables the digital design, testing, and modification of product models; and Onshape, a SaaS product development platform that delivers computer-aided design with data management, collaboration tools, and real-time analytics. Further, it offers Vuforia, an augmented reality (AR) software; and Arbortext, a dynamic publishing solution streamlines how organizations create, manage, and publish technical documentation. PTC Inc. was incorporated in 1985 and is headquartered in Boston, Massachusetts.

PTC Inc.

Morgan Stanley analyst Judah Frommer maintained a Buy rating on PTC Therapeutics today and set a price target of $93.00. Frommer covers the Healthc...

Morgan Stanley Remains a Buy on PTC Therapeutics (PTCT)

Barclays analyst Eliana Merle maintained a Buy rating on PTC Therapeutics today and set a price target of $120.00. Merle covers the Healthcare sect...

Barclays Remains a Buy on PTC Therapeutics (PTCT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tempus AI, Inc. Class A (TEM), Doximity (DOCS) and...

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Doximity (DOCS) and PTC Therapeutics (PTCT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Personalis (PSNL) and PTC Therapeutics (PTCT). Per...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Personalis (PSNL) and PTC Therapeutics (PTCT)

In a report released on July 15, Matthew Hedberg from RBC Capital maintained a Buy rating on PTC, with a price target of $195.00. The company’s sha...

RBC Capital Sticks to Their Buy Rating for PTC (PTC)

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on PTC Therapeutics today and set a price target of $95.00. According to Ti...

PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities

Analysts have been eager to weigh in on the Technology sector with new ratings on PTC (PTC) and Everpure (P). PTC (PTC) In a report released yester...

Analysts Conflicted on These Technology Names: PTC (PTC) and Everpure (P)

PTC Industries Ltd ( ($IN:PTCIL) ) has shared an update. PTC Industries’ board has approved plans to raise up to ₹1,800 crore via qualified institu...

PTC Industries clears major fund-raising and higher borrowing limits

The latest update is out from PTC Industries Ltd ( ($IN:PTCIL) ). PTC Industries Limited has announced that it has been recognised among India’s 50...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTC	$118.52	+4.84%	1.42M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PTC	$118.52	+4.8%	1.42M
3
4
5
6

PTC

PTC

Get PTC Inc. Data in Excel

Get PTC Inc. Data in Excel